Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2010 1
2012 2
2013 1
2014 3
2015 2
2017 1
2019 3
2020 4
2021 6
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for brendan solid
Search for Brendan Solia instead (1 results)
Targeting anti-cancer agents to bone using bisphosphonates.
Xing L, Ebetino FH, Boeckman RK Jr, Srinivasan V, Tao J, Sawyer TK, Li J, Yao Z, Boyce BF. Xing L, et al. Bone. 2020 Sep;138:115492. doi: 10.1016/j.bone.2020.115492. Epub 2020 Jun 23. Bone. 2020. PMID: 32585321 Free PMC article. Review.
The skeleton is affected by numerous primary and metastatic solid and hematopoietic malignant tumors, which can cause localized sites of osteolysis or osteosclerosis that can weaken bones and increase the risk of fractures in affected patients. ...
The skeleton is affected by numerous primary and metastatic solid and hematopoietic malignant tumors, which can cause localized sites …
A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?
Bennett-Lenane H, O'Shea JP, O'Driscoll CM, Griffin BT. Bennett-Lenane H, et al. J Pharm Sci. 2020 Nov;109(11):3248-3261. doi: 10.1016/j.xphs.2020.08.008. Epub 2020 Aug 19. J Pharm Sci. 2020. PMID: 32822721 Review.
Increasing numbers of poorly water soluble drugs in development has intensified need for bio-enabling formulations including Lipid-Based Formulations (LBF) and Solid Dispersions (SD). Resultantly, a data-driven approach is required to increase formulation development effic …
Increasing numbers of poorly water soluble drugs in development has intensified need for bio-enabling formulations including Lipid-Based For …
Metastasis and bone loss: advancing treatment and prevention.
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Coleman RE, et al. Cancer Treat Rev. 2010 Dec;36(8):615-20. doi: 10.1016/j.ctrv.2010.04.003. Epub 2010 May 15. Cancer Treat Rev. 2010. PMID: 20478658 Free PMC article. Review.
Tumor metastasis to the skeleton affects over 400,000 individuals in the United States annually, more than any other site of metastasis, including significant proportions of patients with breast, prostate, lung and other solid tumors. Research on the bone microenvironment …
Tumor metastasis to the skeleton affects over 400,000 individuals in the United States annually, more than any other site of metastasis, inc …
The Time Is Now: Bioethics and LGBT Issues.
Powell T, Foglia MB. Powell T, et al. Hastings Cent Rep. 2014 Sep;44 Suppl 4:S2-3. doi: 10.1002/hast.361. Hastings Cent Rep. 2014. PMID: 25231781
Andrew Solomon offers an elegant overview of the challenges that bioethics faces in articulating a solid basis for LGBT rights. Timothy F. Murphy asks whether bioethics still faces issues related to lesbian, gay, and bisexual people, given the deletion of homosexuality as …
Andrew Solomon offers an elegant overview of the challenges that bioethics faces in articulating a solid basis for LGBT rights. Timot …
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies.
Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, Achour I, Barbee S, May R, Morehouse C, Pollizzi K, Song X, Steele K, Elgeioushi N, Walcott F, Karakunnel J, LoRusso P, Weise A, Eder J, Curti B, Oberst M. Naing A, et al. J Immunother Cancer. 2019 Aug 22;7(1):225. doi: 10.1186/s40425-019-0665-2. J Immunother Cancer. 2019. PMID: 31439037 Free PMC article. Clinical Trial.
BACKGROUND: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. METHODS: MEDI0680 was administered intravenously o …
BACKGROUND: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluate …
Lipophilic Salts and Lipid-Based Formulations for Bridging the Food Effect Gap of Venetoclax.
Koehl NJ, Henze LJ, Holm R, Kuentz M, Keating JJ, De Vijlder T, Marx A, Griffin BT. Koehl NJ, et al. J Pharm Sci. 2022 Jan;111(1):164-174. doi: 10.1016/j.xphs.2021.09.008. Epub 2021 Sep 11. J Pharm Sci. 2022. PMID: 34516990
A subsequent bioavailability study in landrace pigs demonstrated a 2.5-fold higher bioavailability for the lipophilic salt containing long chain SEDDS compared to the commercially available solid dispersion Venclyxto in the fasted state. The bioavailability of all lipophil …
A subsequent bioavailability study in landrace pigs demonstrated a 2.5-fold higher bioavailability for the lipophilic salt containing long c …
In vivo and in vitro α-amanitin metabolism studies using molecular networking.
Le Daré B, Ferron PJ, Couette A, Ribault C, Morel I, Gicquel T. Le Daré B, et al. Toxicol Lett. 2021 Aug 1;346:1-6. doi: 10.1016/j.toxlet.2021.04.006. Epub 2021 Apr 16. Toxicol Lett. 2021. PMID: 33872745 Free article.
Using molecular networking on both in vitro and in vivo, we have demonstrated that alpha-amanitin does not undergo metabolism in human. Thus, we provide solid evidence that a possible production of amanitin metabolites cannot be involved in its toxicity pathways. ...
Using molecular networking on both in vitro and in vivo, we have demonstrated that alpha-amanitin does not undergo metabolism in human. Thus …
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Andtbacka RHI, Curti B, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, Spitler LE, Zhou K, Bommareddy PK, Grose M, Wang M, Wu C, Kaufman HL. Andtbacka RHI, et al. J Clin Oncol. 2021 Dec 1;39(34):3829-3838. doi: 10.1200/JCO.20.03246. Epub 2021 Aug 31. J Clin Oncol. 2021. PMID: 34464163 Clinical Trial.
Response and progression status were based on contrast-enhanced computed tomography, magnetic resonance imaging, or caliper measurement and were categorized using immune-related Response Evaluation Criteria in Solid Tumors (irRECIST). Other evaluations included monitoring …
Response and progression status were based on contrast-enhanced computed tomography, magnetic resonance imaging, or caliper measurement and …
Applying Computational Predictions of Biorelevant Solubility Ratio Upon Self-Emulsifying Lipid-Based Formulations Dispersion to Predict Dose Number.
Bennett-Lenane H, Koehl NJ, O'Dwyer PJ, Box KJ, O'Shea JP, Griffin BT. Bennett-Lenane H, et al. J Pharm Sci. 2021 Jan;110(1):164-175. doi: 10.1016/j.xphs.2020.10.055. Epub 2020 Nov 2. J Pharm Sci. 2021. PMID: 33144233
Increased drug solubility upon SEDDS dispersion was observed in all cases, with higher SRs observed for cationic and neutral versus anionic drugs at pH 6.5. Molecular descriptors and solid-state properties were used as inputs during partial least squares (PLS) modelling re …
Increased drug solubility upon SEDDS dispersion was observed in all cases, with higher SRs observed for cationic and neutral versus anionic …
Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells.
Buckley AM, Bibby BA, Dunne MR, Kennedy SA, Davern MB, Kennedy BN, Maher SG, O'Sullivan J. Buckley AM, et al. Pharmaceuticals (Basel). 2019 Feb 20;12(1):33. doi: 10.3390/ph12010033. Pharmaceuticals (Basel). 2019. PMID: 30791601 Free PMC article.
Cisplatin (cis-diamminedichloroplatinum) is widely used for the treatment of solid malignancies; however, the development of chemoresistance hinders the success of this chemotherapeutic in the clinic. ...
Cisplatin (cis-diamminedichloroplatinum) is widely used for the treatment of solid malignancies; however, the development of chemores …
22 results